@Hallakis tror det er mulig å bestille DDOS av bloodjournal sin hjemmeside også, om du vil ta saken i egne hender. 
bomma med klokka igjen nå eller?
Finner ikke abstraktet.
Nå skjer det folkens!
3 Likes
kanskje det er US delay på noen minutter
Nå går toget!
Results: 74 pts [57 follicular (FL), 7 mantle cell (MCL), 9 marginal zone (MZL), 1 small lymphocytic (SLL)] were enrolled at 13 sites from Dec 2012 to Feb 2018. Median age was 68 (range 38-87; 55% ≥ 65); the median no. of prior therapies was 3 (range 1-9); 48 pts (65%) had received ≥2 prior therapies. Two RP2Ds emerged: a lilotomab pre-dose of 40 mg + 15 MBq/kg Betalutin (“40/15”; Arm 1) and a lilotomab pre-dose of 100 mg/m2 + 20 MBq/kg Betalutin (“100/20”; Arm 4). For all pts, the overall response rate (ORR) was 61%, with 26% complete responses (CR). By subtype, the ORR was 65% (CR 24%) for FL, and 78% (CR 44%) for MZL. FL with ≥2 prior therapies (n=37) had an ORR of 70% (CR 27%). With a median follow-up of 9.1 m (range 4.9-49.5 m), the median duration of response for all pts is 13.3 m (20.5 m for those with a CR); 26 pts (35%) have remained free of disease progression for >12 m [CR(15)/PR(5)/SD(6)].
For the 36 pts receiving the “40/15” regimen, the ORR was 58% (CR 28%), and 64% (CR 28%) for FL (n=25). The ORR was 63% (CR 21%) for 19 pts receiving the “100/20” regimen, and 69% (CR 19%) for FL (n=16).
21 Likes
Nei, men skal kjøpe litt champagne nå.
1 Like
Dette er målgruppen:
FL with ≥2 prior therapies (n=37) had an ORR of 70% (CR 27%).
13 Likes
gode nyheter altså, kjekt
Kan noen poste abstract her?
…Og handelen stoppet noen hjerteslag opp der alle ser rundt seg og spør “Hva i svarte H betyr dette”… 
1 Like
And we have lift-off
1 Like
20/100 strikes back.
5 Likes
der kom meldingen gitt og algoene var klare
Fan ramle meg underholdning på høyt nivå å følge RT nå.
1 Like